Nostrum Laboratories Inc. (Nostrum), located in Missouri and New Jersey, and its founder and CEO, Nirmal Mulye, Ph.D. (Mulye), have agreed to pay a minimum of $3,825,000, and up to $50 million if certain financial contingencies are met, to resolve allegations that they violated the False Claims Act by knowingly underpaying Medicaid rebates due for Nostrum’s drug Nitrofurantoin Oral Suspension (Nitro OS). The settlement is based on Nostrum’s and Mulye’s financial condition. Read More
Home » Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
Related Posts
Former Maury County, Tennessee, Corrections Officer Sentenced for
A former corrections officer of the Maury County, Tennessee, Jail was sentenced yesterday in federal court in Nashville, Tennessee, to 60 months in prison and… BronFormer Maury County, Tennessee, Corrections Officer Sentenced for
Sixteen Cardiology Practices to Pay a Total of $17.7M to Resolve False
Sixteen separate cardiology practices and associated physicians, located across 12 states, have agreed to pay amounts totaling $17,761,564 to resolve allegations that they each violated… BronSixteen Cardiology Practices to Pay a Total of $17.7M to Resolve False
United States Joins Lawsuit Against Former Executives of Kabbage Inc.
The United States has intervened and filed a complaint against Robert Frohwein, Kathryn Petralia and Spencer Robinson, three former executives of Kabbage Inc., a now-bankrupt… BronUnited States Joins Lawsuit Against Former Executives of Kabbage Inc.